785 articles
PARP inhibitors have transformed cancer treatment, but resistance and toxicity are emerging as serious limits to their long-term effectiveness.
Rafael Holdings secures exclusive MIT patent rights for cyclodextrins in ApoE4-positive Alzheimer's patients, a group representing up to 70% of cases.
An $80M family study, 37 proteins in centenarian blood, and a call to rethink aging as a systems failure — here's what's new.
An $80M family study, 37 proteins in centenarian blood, and a call to treat aging as a systems failure converge in new research.
Recent NIA research highlights span brain cell aging, caloric restriction benefits, and cellular senescence — key pillars of longevity science.
Regeneron's Otarmeni marks a historic milestone as the first FDA-approved gene therapy targeting a rare genetic form of hearing loss.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
From cancer-sniffing dogs to liquid biopsies, new research highlights early detection breakthroughs and a growing colorectal cancer crisis in young adults.
Deramiocel slowed upper limb decline by 54% and preserved heart function in boys with Duchenne muscular dystrophy in a landmark phase III trial.
Two new studies show GLP-1 drugs like tirzepatide significantly reduce cardiovascular events in patients undergoing TAVR and carotid artery stenting.
New trial data shows 4,000 IU daily vitamin D3 cuts diabetes risk by 19% — but only in people with specific genetic variants.
Scientists used three Yamanaka factors to help mouse heart muscle cells complete division, reducing scar tissue after heart attacks.
